Clinical trials: Chronic Obstructive Pulmonary Diseases
Pulmonary Disease, Chronic Obstructive
GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
This 2-part study will be carried out on healthy elderly subjects to evaluate relative bioavailability of danirixin formulations.
- Trial name
- NCT03457727
- Testing
- Danirixin, Omeprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, COPD
Prospective evAluatIon foR Inhalation Devices Study
ASTHMA: Asthma is a chronic inflammatory disorder of the airways in which many different types of cells, and various cellular components.
- Trial name
- PAIR (NCT01800994)
- Where
- 6 sites in Greece
- Volunteers
- 750 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Asthma, Chronic Obstructive Pulmonary Disease
Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD
A non-interventional study to assess the clinical effectiveness of Salmeterol/fluticasone Easyhaler to achieve and maintain asthma or COPD control.
- Trial name
- SUNNY (NCT03755544)
- Where
- Germany
- Volunteers
- 231 people
- Sponsor
- Orion Corporation, Orion Pharma
COPD
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease…
- Trial name
- ZION (NCT06496620)
- Testing
- Biological: Solrikitug low dose, Biological: Solrikitug high dose
- Where
- 110 sites in United States, Australia and 2 more
- Volunteers
- 182 people
- Sponsor
- Uniquity One (UNI)
Pulmonary Disease, Chronic Obstructive
Respiration Rate Monitoring in COPD Patients
Assess the feasibility of using remote respiration rate monitoring as a component of home care, how respiration rate data may be used in combination with other data to potentially improve response to symptoms, and to generate…
- Trial name
- NCT03030313
- Testing
- Reassure Non-Contact Respiration Monitor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- ResMed
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140346
- Testing
- RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Respivert Ltd
COPD (Chronic Obstructive Pulmonary Disease), Obesity Hypoventilation Syndrome (OHS)
Assessment of Breathing Pattern During NIV
COPD and OHS are respiratory conditions that disrupt normal breathing. Positive airway pressure, specifically Non-Invasive Ventilation (NIV), has been shown to improve breathing and reduce symptoms in patients with these…
- Trial name
- NCT06682286
- Testing
- NIV mask A, NIV mask B
- Where
- New Zealand
- Volunteers
- 40 people
- Sponsor
- Fisher and Paykel Healthcare
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
- Trial name
- NCT00683722
- Testing
- Prochymal™
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Mesoblast, Inc.
Pulmonary Disease, Chronic Obstructive
Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI 1744 CL.
- Trial name
- NCT01809262
- Testing
- single dose of 5 mcg, single dose of 40 mcg, single dose of 20 mcg
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Asthma
Study of Daclizumab in Patients With Chronic, Persistent Asthma
The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to…
- Trial name
- NCT00028288
- Testing
- Daclizumab
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Facet Biotech
Chronic Obstructive Pulmonary Disease
A Study in Patients With Chronic Obstructive Pulmonary Disease
The primary objective of the study was to demonstrate the superiority of Foster® 100/6 (two puffs b.i.d.) versus Seretide® 500/50 (one inhalation b.i.d.), in terms of pulmonary function (AUC0-30min standardized by time of change…
- Trial name
- FUTURE (NCT01245569)
- Testing
- Beclomethasone Dipropionate - Formoterol, Fluticasone - Salmeterol
- Where
- 68 sites in Denmark, France and 8 more
- Volunteers
- 419 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary…
- Trial name
- NCT06154837
- Testing
- GSK3862995B
- Where
- 32 sites in United States, Germany and 1 more
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease
Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease
The study is to evaluate the percentage of patients with asthma or COPD achieving disease control
- Trial name
- SPRINT (NCT02419872)
- Testing
- Marketed antagonists
- Where
- 141 sites in Croatia, Denmark and 8 more
- Volunteers
- 1,743 people
- Sponsor
- Teva Pharmaceuticals Europe
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to investigate the efficacy and safety of Ba679BR powder inhalation during the continuous once/day administration to the patients with COPD using oxitropium bromide (Tersigan® aerosol) as the comparator drug.
- Trial name
- NCT02172807
- Testing
- Tiotropium low, Tiotropium high, Oxitropium
- Volunteers
- 201 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
REported Outcomes in COPD With Trixeo in Real worlD
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms (including breathlessness, cough, and sputum production), which has a substantial impact on health-related quality of life (HRQoL).
- Trial name
- RECORD (NCT05213611)
- Where
- 31 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Alpha 1-Antitrypsin Deficiency
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
The purpose of this clinical study is to assess the safety and tolerability of Alpha-1 MP in adult Alpha1-antitrypsin deficient patients.
- Trial name
- STAMP (NCT00301366)
- Testing
- alpha-1 proteinase inhibitor (human)
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 38 people
- Sponsor
- Grifols Therapeutics LLC
Pulmonary Disease, Chronic Obstructive
Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy
The purpose of the study is to measure changes in physical functioning in chronic obstructive pulmonary disease (COPD) patients being treated with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.
- Trial name
- OTIVACTO (NCT03003494)
- Testing
- Spiolto® Respimat®
- Where
- 28 sites in Italy
- Volunteers
- 306 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)
Batefenterol (BAT) is a novel bifunctional molecule that combines muscarinic antagonism and beta2-agonism in a single molecule and is in development for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02666287
- Testing
- BAT/FF, BAT, FF
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients
Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in blood, and on pulmonary function) and on pharmacokinetics of CHF…
- Trial name
- NCT01730404
- Testing
- CHF6001 DPI, Roflumilast
- Where
- 5 sites in Ireland, United Kingdom
- Volunteers
- 55 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide 50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and the same dose of Berodual® delivered via an…
- Trial name
- NCT02176200
- Testing
- Berodual® Respimat®, low inspiratory flow rate, Berodual® Respimat®, medium inspiratory flow rate, Berodual® Respimat®, high inspiratory flow rate
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.